TuHURA Biosciences Acquires Kineta

Biogen Acquires Human Immunology Biosciences for up to $1.8B

May 22, 2024

Biotechnology

Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.

Petauri Health (Oak Hill) Acquires The Kinetix Group

June 13, 2023

Healthcare Services

Petauri Health, a pharmaceutical commercialization platform formed by Oak Hill Capital, has acquired The Kinetix Group (TKG), a New York–based market access, access marketing, and medical affairs agency. The Kinetix founders will remain in leadership roles as TKG becomes the inaugural add-on to the Petauri platform, expanding the platform's market access, medical affairs, and real-world evidence capabilities.

Bristol Myers Squibb Acquires Karuna Therapeutics

December 22, 2023

Biotechnology

Bristol Myers Squibb has agreed to acquire Karuna Therapeutics for $330 per share in an all-cash transaction valued at approximately $14.0 billion (about $12.7 billion net of cash). The acquisition adds Karuna's lead neuroscience asset KarXT and its early-stage pipeline to BMS's neuroscience portfolio, accelerating capability and late-stage product expansion in psychiatric and neurodegenerative disorders.

ATAI Life Sciences Acquires Majority Stake in Kures

July 9, 2020

Biotechnology

ATAI Life Sciences AG acquired a majority stake in New York–based pharmaceutical company Kures to advance Kures' mitragynine-derived therapeutic candidates (KUR-101 and KUR-002) targeting pain and opioid use disorder. The deal brings Kures onto ATAI's biotech platform and appoints ATAI CSO Srinivas Rao as Kures CEO to accelerate development and integrate the assets into ATAI's mental-health-focused pipeline.